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ABSTRACT: The tyrosine kinase A (TrkA) receptor is a
validated therapeutic intervention point for a wide range of
conditions. TrkA activation by nerve growth factor (NGF)
binding the second extracellular immunoglobulin (TrkAIg2)
domain triggers intracellular signaling cascades. In the
periphery, this promotes the pain phenotype and, in the
brain, cell survival or diﬀerentiation. Reproducible structural
information and detailed validation of protein−ligand
interactions aid drug discovery. However, the isolated TrkAIg2
domain crystallizes as a β-strand-swapped dimer in the absence
of NGF, occluding the binding surface. Here we report the
design and structural validation by nuclear magnetic resonance
spectroscopy of the ﬁrst stable, biologically active construct of the TrkAIg2 domain for binding site conﬁrmation. Our structure
closely mimics the wild-type fold of TrkAIg2 in complex with NGF (1WWW.pdb), and the 1H−15N correlation spectra conﬁrm
that both NGF and a competing small molecule interact at the known binding interface in solution.
■ INTRODUCTION
The human tyrosine kinase receptor family is comprised of TrkA,
TrkB, and TrkC. TrkA and TrkB have become targets for drug
discovery for treating conditions ranging from pain and cancer to
schizophrenia and Alzheimer’s disease.1,2 Here we focus on the
design and structure determination of a stable construct of the
extracellular TrkAIg2 domain suitable for use in NMR to provide
binding site information in drug discovery projects.
In the periphery, TrkA mediates nociceptive sensitization
when its cognate ligand NGF binds. The Trk receptors are
comprised of a leucine/cysteine rich domain and two
immunoglobulin-like domains, Ig1 and Ig2, in the extracellular
region linked to an intracellular kinase domain by a single
membrane-spanning helix. The Ig2 domain is proximal to the cell
membrane and provides the NGF binding site as was ﬁrst
indicated by Urfer et al.3 and later shown by X-ray
crystallography.4,5 NGF is a homodimeric protein presenting
two TrkA binding sites on opposite faces of the dimer. The
binding of NGF brings together two TrkA receptors triggering
autophosphorylation of their intracellular kinase domains.
Autophosphorylation provides binding sites for proteins
involved in downstream signaling in the phosphatidylinositol-3
(PI3) -kinase, mitogen-activated kinase/extracellular-signal-
regulated kinase (MAP kinase/ERK), and phospholipase C-γ
(PLC-γ) pathways.6,7 Consequentially, NGF activation of TrkA
modulates the activity of both ligand and voltage-gated ion
channels involved in nociception via the following mechanisms.
Under resting conditions, the ligand-gated transient receptor
potential cation channel vanilloid subfamily member 1 (TRPV1)
is constitutively inhibited by phosphoinositol 4,5-bisphosphate
(PIP2) on nociceptors. The activation of PLC-γ downstream of
TrkA activation by NGF relieves this constitutive inhibition by
hydrolyzing PIP2 to inositol 1,4,5-trisphosphate (IP3) and
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diacylglycerol.6 This lowers the threshold of activation of TRPV1
and other ion channels. Pain signaling is enhanced by the release
of brain derived neurotrophic factor (BDNF), substance P, and
other peptides which are transported to the dorsal root ganglion
(DRG), subsequently promoting central pain perception.8 The
activation of TrkA by NGF thus initiates the chronic pain
phenotype by increasing nociceptor sensitivity to further
stimulus.9 During the sensitization process, TrkA expression is
itself up-regulated on nociceptors, as are the ion channels Nav1.8,
P2XY, and TRPV1.10
However, within the brain, TrkA function is fundamental to
memory formation and learning.1 Cholinergic cells of the basal
forebrain extend axons into the hippocampus and cerebral cortex
and depend on the supply of NGF delivered by axonal retrograde
transport.11 Activation of TrkA by NGF triggers the afore-
mentioned signaling cascades to provide support for neurite
growth and repair and maintenance of eﬀective connectivity
between the cholinergic basal forebrain, hippocampus, and the
cortex for the formation of new memories. Early in the
progression of Alzheimer’s disease, TrkA/NGF signaling in the
cholinergic cells of the basal forebrain is compromised, the cells
undergo axonal withdrawal, and as a result, brain regions no
longer communicate eﬃciently. This contributes to short-term
memory impairment and confusion.
TrkA is a validated target for pain therapeutics in both animal
models and in the clinic. NGF based therapeutics in animal
models of pain including the NGF binding domain on TrkA
(TrkAIg2)12−15 and anti-NGF antibodies including Tanezu-
mab16,17 have successfully provided relief from acute and chronic
pain states in clinical trials.18 However, several antibody therapies
have had serious side eﬀects19 which may arise from the high
aﬃnity of the antibody/target interaction combined with the
very long half-life of the NGF antibody, making bioavailability
hard to predict and hence control by dosing.
Identifying small molecule therapeutics targeted to the
extracellular TrkA domain to disrupt the TrkA/NGF protein−
protein interaction provides a major challenge, and high-
throughput screens have failed to produce small molecule
antagonists to this target. Kinase inhibitors speciﬁc for TrkA are
diﬃcult to achieve as the intracellular kinase domains are highly
conserved between the Trk receptors: A to B, 75% identity, A to
C, 76% identity, and B to C, 82% identity and all have almost
identical ATP binding sites.
Targeting the extracellular NGF binding domain of TrkA, the
TrkAIg2 domain, provides potential advantages for two main
reasons: inﬂuencing the extracellular ligand binding interaction
represents the preampliﬁcation stage in the signaling cascades
where nature “ﬁne-tunes” receptor-mediated events; the neuro-
trophin binding domains share lower sequence identity between
Trk receptors: A to B, 46%, A to C, 41%, and B to C, 47%, making
speciﬁc targeting more readily achievable. Compounds that can
prevent NGF-mediated activation of TrkA on peripheral
nociceptors will be useful in the management of pain and
those capable of acting centrally to augment NGF-mediated
activation of TrkA could be developed as Alzheimer’s
therapeutics to support the cholinergic system.
To develop TrkAIg2 domain binders, access to reproducible
structural information is required to conﬁrm the compound
binding site. Crystallography has proven to be problematic
because at high concentrations the isolated Ig2 domain forms β-
strand-swapped dimers (1WWA.pdb) in the absence of its
cognate ligand NGF and is thus biologically inactive.4 Strand-
swapping occludes not only the NGF binding site but also the
compound binding sites targeted.
We describe the design and validation of a TrkAIg2-NMR
construct in which we have stabilized the native fold (not strand-
swapped) and retained biological activity. Here we use solution
NMR to determine the three-dimensional structure of the
protein and validate the use of the construct using NGF and a
small molecule (amitriptyline) in both NMR binding experi-
ments and functional assays. This approach should greatly
facilitate the development of small molecule leads for modulating
the activity of TrkA and related receptors.
■ RESULTS AND DISCUSSION
Design of the NMR Construct TrkAIg2-NMR. Initially, we
selected an in-house construct spanning the second Ig domain of
TrkA that we refer to as “wild-type” TrkAIg2 (TrkAIg2-WT)
(Figure 1A). This construct has been used successfully to
sequester NGF and abrogate pain in a number of in vivo
models12−15 and was therefore used for initial NMR studies. A
15N-labeled sample of the TrkAIg2-WT construct was prepared
and a two-dimensional 1H−15NHSQCNMR spectrum recorded
(Figure 1B). This spectrum displayed many unfavorable features
for structural and ligand-binding assays, including overlap and
Figure 1. (A) Sequence comparison of “wild-type” TrkAIg2-WT domain, the ﬁrst-generation engineered cysteine mutant (TrkAIg2-DS1), the ﬁnal
construct produced for solution NMR studies (TrkAIg2-NMR), and the construct used in X-ray crystallographic studies of the strand-swapped dimer
(TrkAIg2-Xt1).20 (B) 1H−15N HSQC spectra of the wild-type construct TrkAIg2-WT. The amide peak dispersal indicates that the protein is not a
homogeneous population or that some of the structure is disordered.
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heterogeneity of signal intensity (e.g., a mixture of intense and
weak broadened cross-peaks).
To engineer a construct for use in the absence of NGF, we re-
examined known crystal structures of these proteins. The X-ray
crystallographic study of the wild-type single TrkA-Ig2 domain
(Figure 2A) bound to NGF previously revealed twomolecules of
the TrkA-Ig2 domain bound to a central NGF dimer.5 An
extensive interface was observed between NGF and the
individual TrkA-Ig2 domains, but there were no direct contacts
between the TrkA-Ig2 domains themselves. When studied in
isolation, however, the Ig2 domains from TrkA, TrkB, and TrkC
have all been shown to form strand-swapped dimers in solved
crystal structures (Figure 2B), an association that occludes the
interaction site on TrkA for NGF. Therefore, at high
concentrations, the formation of oligomeric4 species in addition
to unstructured regions might explain the poor NMR character-
istics of the TrkAIg2-WT construct. Figure 2C shows an overlay
of a single TrkA-Ig2 domain chain from the strand-swapped
crystal structure 1HE7.pdb with a single chain from the crystal
structure 1WWW.pdb in complex with NGF. The strand-
swapped structure of TrkA-Ig2 (residues 285−413), studied by
Robertson et al., revealed a stable core structure extending to
P382 after which no electron density was observed.20 The C-
terminal was presumed to be ﬂexible and might not therefore be
ideal for solution-state NMR studies. Therefore, the C-terminal
was truncated to end in the residues DNPF (383) (Figure 1A).
To prevent β-strands swapping between adjacent monomers at
high concentrations, an additional disulﬁde bond was also
introduced to act as an intramolecular staple between β-strand 1
(P285C) and the β-hairpin between strands 6 and 7 (F367C,
Figure 1A) to yield our ﬁrst-generation construct TrkAIg2-DS1.
The disulﬁde bridge was modeled onto chain X of TrkA from the
crystal structure 1WWW.pdb and then energy minimized using
Discover 2.98 (Accelrys) (Figure 2D). These residues were
chosen because they were suitably distant from the NGF binding
face of the protein and therefore less likely to inﬂuence the
binding of compounds to the target site. P285 and F367 were
already almost the optimal distance apart required for disulﬁde
bond formation. In the crystal structure, their side chains were
oriented toward each other so that disulﬁde formation between
two cysteines at these positions would be predicted to cause
minimal distortion to the overall fold. Importantly, these residues
fulﬁlled another necessary criterion21 predicted to produce a
hyper-stable native state, namely they were not involved in the
hydrogen bonding pattern of the β-sheet.
Comparison of the predicted model of TrkAIg2-DS1 with the
crystal structure of the strand-swapped dimer (Figure 2C) shows
the expected drastic change in the packing of the N-terminal
strand but minimal perturbation to the remainder of the protein.
Similarly, comparison of the predicted model with the non-
strand-swapped crystal structure of the TrkA-Ig2 domain in
complex with NGF shows only small perturbations in the region
of the disulﬁde bridge which were unlikely to inﬂuence the more
distant NGF binding site (Figure 2D).
TrkAIg2-DS1 was expressed and puriﬁed but yields of protein
were low, so a further construct which included an additional 5
N-terminal aspartates (TrkAIg2-NMR) was produced (Figure
1A). The hypothesis was that an increased overall negative
Figure 2. Comparison of X-ray crystallographic structures and modeled TrkA-Ig2 in free forms and complexed with NGF. (A) Crystal structure of the
complex between NGF and TrkA-Ig2 (1WWW.pdb)20 with two molecules of TrkA-Ig2 shown in magenta in binding to an NGF dimer (slate). (B)
Crystal structure of two molecules of TrkA-Ig2 (red and light-orange) in the absence of NGF forming a strand-swapped dimer (1WWA.pdb).4 (C)
Superposition of the X-ray structure of a further strand-swapped dimer of TrkAIg2 (PDB code 1HE7)20 (cyan) with the position of P285 and F367
highlighted. The structure of modeled domain 5 (green) is shown incorporating the P285C and F367C mutations and the new disulﬁde bond after
energy minimization. The fold is predicted to be minimally perturbed when this disulﬁde is introduced. The N-terminal strand in the modeled construct
is highlighted with *, and the point at which the non- and strand-swapped dimers diverge is indicated by **. (D) Similarly, superposition of the
minimized disulﬁde bridged construct shows close structural similarity with the packing of the N-terminal β-strand in the NGF bound crystal structure
(1WWW.pdb).
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charge (pI with aspartates 4.52) might reduce nonspeciﬁc
association during refolding and reduce the potential for
inappropriate disulﬁde bonding during the refold by not having
the cysteine at position one in the sequence.
Yields of the second-generation protein, termed TrkAIg2-
NMR, were improved as the proportion of protein aggregating
on refold was signiﬁcantly reduced. Biological activity was
determined through the ability of TrkA constructs to bind and
sequester NGF. The TrkAIg2-NMR reduced cell survival (Figure
3A) with an EC50 of 2.1 μM compared with TrkAIg2-WT EC50
0.48 μM). TrkAIg2-NMR inhibition of NGF-induced neurite
outgrowth on PC12 cells (Figure 3B) gave an EC50 of 1.59 μM.
This construct also sequestered radiolabeled NGF in competi-
tion assays with an approximate IC50 of 5 μM on HEK cells
expressing human TrkA (Figure 3B, inset). Biological activity
was conﬁrmed for each batch of TrkAIg2-NMR protein
produced. A MALDI-TOF spectrum conﬁrmed the presence
of a single monomeric species and no disulﬁde-linked dimer was
detected and native gel electrophoresis showed a single band
(Supporting Information, Figure S1). Analytical ultracentrifuga-
tion of the TrkAIg2-NMR construct conﬁrmed that the protein
was monomeric under the conditions used for the NMR studies
(Supporting Information, Figure S1), and gel ﬁltration showed a
single symmetrical peak (Figure 3C). Taken together, these
results indicate the construct was a monomeric homogeneous
fold.
A 1H−15N HSQC was recorded on a 15N-labeled sample of
TrkAIg2-NMR (Figure 3D) and showed distinct improvements
to both peak dispersion and uniformity of peak height. This
construct also had the advantage of being stable for at least three
months at 25 °C and provided reproducible HSQC spectra
between preparations.
Assignment and Three-Dimensional Structure Deter-
mination. The assignment of the 1H, 13C, and 15N resonances of
TrkAIg2 were obtained using a 13C, 15N labeled sample of
TrkAIg2-NMR and triple resonance experiments recorded at
600 MHz. Overall, 98% of the backbone resonances could be
assigned, with missing residues being located in the N-terminal
Asp-rich region; 94% of the side-chain resonances could be
assigned. Again missing resonances were primarily located in the
N-terminal region.
The solution structure was determined using a total of 182
dihedral angles, 46 hydrogen bonds, and 2053 NOEs derived
from 3D 15N-edited NOESY-HSQC, 13C aromatic HSQC-
NOESY, and simultaneous 15N/13C-edited NOESY spectra. The
ﬁnal twenty structures chosen to represent the ensemble of NMR
structures (Figure 4A) were consistent with both experimental
data and standard covalent geometry, displaying no violations
greater than 0.5 Å for distance restraints or 5° for dihedral angles.
The averaged structure for the ensemble highlights the position
of the disulﬁde staple (Figure 4B). Details of the ﬁnal set of
structural restraints and their violations within the ﬁnal ensemble
are listed in Table 1.
The core of TrkAIg2-NMR is well-deﬁned, with a backbone
rmsd from the mean over the regular secondary structure
elements of 0.38 Å for the ensemble of structures. As expected,
the solution structure forms an Ig-like fold consisting of a β-
sandwich formed by two β-sheets. The structure is highly similar
to the 2.2 Å crystal structure of TrkA in complex with NGF
solved at pH 5.0 (1WWW.pdb)5 with a backbone rmsd over the
secondary structure elements of 0.68 Å (ProFit v2.5) (Figure
4C). As expected, the introduction of a disulﬁde bond between
Figure 3. Functional and biophysical characterization of TrkAIg2-NMR
compared to TrkAIg2-WT. (A) TrkAIg2-NMR and TrkAIg2-WT eﬀect
on NGF-dependent cell proliferation in PC12 cells. Both the TrkAIg2-
WT (closed circles, EC50 0.48 μM) and the TrkAIg2-NMR (open
circles, EC50 2.1 μM) forms were able to sequester NGF and prevent cell
proliferation in a dose-dependent manner. (B) The eﬀect of TrkAIg2-
NMR on NGF-mediated neurite outgrowth in PC12 cells: 0.04 nM
NGFwas added to PC12 cells in addition to a range of concentrations of
15N labeled TrkAIg2. The TrkAIg2-NMR construct inhibited neurite
outgrowth with an EC50 1.59 μM. Inset:
15N-labeled TrkAIg2-NMR
mediated sequestration of 125I-labeled NGF in a competition assay
against full-length human TrkA receptors expressed on HEK cells, with
an approximate IC50 of 2 μM. (C) Complex formation between
TrkAIg2-NMR andNGF. TrkAIg2-NMR andmouse NGFwere applied
to a gel ﬁltration S75 column, separately and as a 1:1 ratio complex of
two monomers of TrkAIg2-NMR with one dimer of NGF. The
TrkAIg2-NMR/NGF complex (Mwt 51 kDa) was shown to run at 57
kDa as estimated by a calibration curve. Alone, TrkAIg2-NMR (Mwt of
monomer is 11.9 kDa) ran at 17 kDa; NGF (27 kDa dimer) ran at 18.8
kDa. (D) 1H−15N HSQC spectra of TrkAIg2-NMR, showing vastly
improved homogeneity of peak intensity and line shape.
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P285 and F367 to help stabilize the protein does not aﬀect the
overall structure.
Minor diﬀerences in the solution and crystal structures are
observed in the loop regions due to pH or conformational
changes. The complex was crystallized by hanging drop in 1:1
protein solution:Hampton screen. The protein solution was 10
mgmL−1 complex (TrkA andNGF) in 0.1MNaCl, 0.1M bicine,
pH 8.5, the Hampton screen condition comprised of 24% PEG
3350, 0.1 M citric acid, pH 5.0 (1WWW.pdb). Buﬀer conditions
for the NMR were 100 mM sodium phosphate pH 6.9 and 10
mM NaCl. No evidence of dimer formation was observed in the
NMR experiments, and testing the calculated models against a
possible dimeric stoichiometry gave no improvement in the ﬁt to
the NOE data or minimized energies.
Structure−Function Validation: The TrkAIg2-NMR
Protein Binds NGF, the Cognate Ligand for TrkA. We
then tested whether we could detect a direct protein−protein
interaction in solution under conditions used for NMR with the
TrkA receptor’s cognate ligand, the cytokine NGF (from mouse
submaxillary salivary glands22). NGF readily adsorbs onto many
surfaces,23 but reversible acid denaturation reduces this
propensity. NGF is therefore stored in sodium acetate at pH 2
to minimize losses. A single-shot NMR assay was recorded to
ensure that no pH perturbation occurred when the complex was
formed as 650 μg of NGF (preadjusted to pH 6.9) was added to a
solution of 15N-TrkAIg2-NMR to approach a 1:1 stoichiometry.
Complex formation was conﬁrmed by gel ﬁltration (Figure 3C).
Figure 5A shows the 1H−15N HSQC spectra before (black) and
after (red) the addition of a stoichiometric concentration of
NGF. A number of residues show either amide chemical shift
perturbations (CSPs) or are signiﬁcantly line broadened in the
presence of NGF (Figure 5B). These perturbed residues were
mapped onto the crystal structure of the TrkAIg2 domain bound
to NGF and are shown in Figure 5C,D. Although the CSPs are
<0.15 ppm,24 the predominant spectral changes cluster around
Figure 4. Solution structure of TrkAIg2-NMR and comparison with the
crystal structure. (A) The ensemble of 20 TrkAIg2-NMR domain
structures. The NGF binding groove is indicated with a dotted line. (B)
The closest to the geometric average solution structure with the position
of the disulﬁde staple shown between C285 and C367. (C) An overlay of
chain X from the crystal structure of the TrkAIg2/NGF complex
(magenta, 1WWW.pdb)20 and the closest to the geometric average
NMR model of the TrkAIg2-NMR (green) construct showing that the
disulﬁde bridge has not disrupted the global protein fold.
Table 1. Structural Restraints and Violations of the Final
Structures
completeness of resonance assignmentsa
backbone/non-H (%) 92.8/93.6
side chain H/non-H (%) 94.7/75.7
conformational restricting restraints
total NOE restraints 2053
intraresidue 910
sequential/medium range (residue i to i+(1−5) 637
long-range 453
ambiguous 53
dihedral angle restraints 182
hydrogen-bonds restraints 46
disulﬁde restraints 2
residual restraint violationsb
average no. of distance angle violations per structure
>0.1 (Å) 3.88
>0.3 (Å) 0
>0.5(Å) 0
average no. of dihedral angle violations per structure
>5° 0
model qualityb
rmsd backbone 2° structure atoms (Å) 0.38 (±0.068)
rmsd heavy 2° structure atoms (Å) 0.77 (±0.066)
rmsd backbone all atoms (Å) 1.34 (±0.30)
rmsd heavy all atoms (Å) 1.81 (±0.32)
rmsd bond lengths (Å) 0.016
rmsd bond angles (deg) 1.3
MolProbity Ramachandran statisticsc
most favored regions (%) 97.3
allowed regions (%) 2.4
disallowed regions (%) 0.2
global quality scores (raw/Z scores)c
Verﬁy3D 0.27/−3.05
ProsaII 0.23/−1.74
Procheck (Φ−ψ) −0.58/−1.97
Procheck (all) −0.45/−2.66
MolProbity clash score 15.97/−1.12
BMRB accession number 19824
PDB ID code 4crp
aCcpNmr Analysis v2.3.1.28,29 bCNS/Aria 2.3.32−34 cCalculated using
PSVS 1.5.35
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the groove formed by strands β2, β4, and β5 that binds the N-
terminal helix of NGFwith several additional residues in the loop
connecting strands β5 and β6.5 In particular, residues which are
almost completely line broadened (shown as green bars in Figure
5B) form a patch centered in the binding groove which would
contact the helix (Figure 5C). This N-terminal helix is
unstructured when NGF is crystallized in the free form
(1BET.pdb), and electron density is only visible for this region
when NGF is in complex with the TrkAIg2 domain
(1WWW.pdb) and makes an energetically important contribu-
tion to the binding energy of the TrkAIg2/NGF interaction.25
We note however that the observed peak broadening is not as
pronounced as expected if a large, stable complex was formed
with NGF (Kd low micromolar), suggesting that not all of the
NGF was available in solution, perhaps due to binding to the
glass of the NMR tube and the TrkAIg2-NMR remains well in
excess.
The NGF and Amitriptyline Binding Sites Overlap.Next
we tested whether we could observe an interaction of TrkAIg2-
NMR with a small molecule ligand. The National Institute for
Health and Clinical Excellence (NICE) supports the use of
amitriptyline for the management of neuropathic pain, and
therefore amitriptyline was one of a number of similar
compounds tested in vitro by us and found to displace 125I-
NGF from human TrkA expressed on HEK cells (see below).
Amitriptyline was therefore used in a NMR 1H−15N HSQC
titration as a positive small molecule control. Addition of
amitriptyline to TrkAIg2-NMR (100 μM) gave over 20
observable amide CSPs with ﬁve >0.224 (Figure 6B). The
CSPs observed saturate with increasing amitriptyline concen-
tration, allowing the extraction of the Kd values for four residues
(T292 Kd 1.8 mM ± 0.2 mM, V305 Kd 2.1 mM ± 0.4 mM, C345
Kd 2.1 mM± 0.4 mM, F303 Kd 2.2 mM± 0.1 mM) (Figure 6C).
The diﬀerence in Kd observed for amitriptyline binding to
TrkAIg2-NMR versus the IC50 observed with full-length TrkA
indicates some loss of aﬃnity when utilizing this engineered
single domain. Although the Kd is only in the mM range, this low
molecular weight species (which lies within the <300 Da
fragment classiﬁcation) shows 13 common perturbed residues
(CSP or line broadening) with NGF (Figures 5A and 6A,B) and
include L290, T292, G344, C345, L346, and L348. These
residues again map to the groove on the TrkAIg2 domain formed
by strands β2, β4, and β5 and interconnecting loops where theN-
terminal helix of NGF binds (“Site 1”). Several larger CSPs,
however (e.g., S304 and V305), are only signiﬁcantly perturbed
by amitriptyline and arise from residues that lie within a narrower
groove formed between stands β1 and β2 adjacent to the NGF
helix binding site (“Site 2”). To further explore the bound
conformation of amitriptyline, the compound was initially
positioned by hand guided by the clustered CSPs at the known
NGF binding site. Amitriptyline was then docked into the
binding site on the TrkAIg2 domain using Bristol University
Docking Engine (BUDE)26 and poses judged against ﬁts to the
observed 1H CSPs.27 Seven of the top 10 poses from BUDE
docking with best predicted binding energies were selected (see
Supporting Information, Figure S4 and Table S1). A
representative conformer from these models is shown in Figure
6D and covers both site 1 and site 2 deﬁned by the CSPs.
Amitriptyline binding in this position would be expected to
interfere with NGF binding at site 1 as illustrated but does not
completely occlude the NGF N-terminal helix binding groove
(Figure 6D). The model also shows that amitriptyline binding
extends somewhat beyond the binding site of the N-terminus of
Figure 5. Interaction of NGF with TrkAIg2-NMR. (A) the overlaid
1H−15N HSQC spectra of TrkAIg2-NMR construct before (black) and
after (red) the addition of stoichiometrically equivalent quantity of
NGF. Resonances that show chemical shift perturbations (CSPs) or
appear signiﬁcantly broadened have been annotated. (B)ΔδNH between
free TrkAIg2-NMR and NGF present (orange), where the height is
proportional to the diﬀerence in ppm.Negative green peaks indicate that
line-broadening was observed but no CSP. The majority of the residues
that show CSPs or line broadening interact with the N-terminus of NGF
that forms a helix on binding the TrkAIg2 domain. (C) Surface
representation of TrkAIg2-NMR (dark-gray) and NGF (cyan) with
CSPs and line broadening shaded orange and exchange-broadened
peaks only shaded green. (D) NGF (cyan) is depicted in secondary
structure as a ribbon in complex with one TrkAIg2-NMR (green), with
residues corresponding to the peaks shifted in the 1H−15N HSQC
spectrum drawn as sticks.
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NGF to site 2. This may have implications for the design of
further small molecule binders targeting TrkA.
Amitriptyline Competes with NGF for Binding to the
Full-Length Human TrkA Expressed on HEK Cells. Dose
related displacement of 125I-NGF by amitriptyline was assessed
using a competition assay (see Materials andMethods). The acid
salt of amitriptyline is freely soluble in water; therefore, to avoid
any unforeseen eﬀects, dimethyl sulfoxide (DMSO)was not used
in any assays or NMR experiments. Our results showed that
amitriptyline competes with radiolabeled NGF for binding to
human TrkA with an IC50 60 μM (Figure 6E). Automated
immunoﬂuorescence (InCell) analysis also shows that amitripty-
line inhibits the phosphoERK signal induced downstream of
TrkA activation by 0.5 nMNGF onHEK cells expressing the full-
length human TrkA receptor with an EC50 of approximately 86
μM (Figure 6F). Evidence of competition with respect to NGF
on cells expressing human TrkA corroborates the observed peak
shifts on the TrkA-Ig2-NMR, both indicating binding site overlap
between amitriptyline and NGF.
■ CONCLUSIONS
The TrkA/NGF interaction is an important and well-validated
target for pain intervention. By modifying the TrkAIg2 domain,
we have produced a valuable tool for assessing the binding of
compounds to a site on TrkA in order to inhibit the binding of
NGF. The main problems we have overcome were protein
ﬂexibility and strand-swapping at high concentrations. Protein
ﬂexibility was reduced by truncating the C-terminus to exclude
Figure 6.TrkAIg2-NMR constructs interacts with a small molecule, amitriptyline. (A) Peak shifts attributed to amitriptyline binding. (B)ΔδNH between
free and amitriptyline bound TrkAIg2-NMR (blue), where the height is proportional to the diﬀerence in ppm. Also shown are the CSPs for the
interaction with NGF for comparison (orange). The negative points again indicate that line broadening was observed but no signiﬁcant CSP. (C)
Titration with amitriptyline provides a saturable signal. F303 and G344 show amide peaks shift with titrated amitriptyline, and both the change in peak
positions and the resulting chemical shift change versus amitriptyline curves are shown as insets. (D) Amitriptyline docked into the groove identiﬁed by
peak shifts and inset surface representation of amitriptyline docked into TrkAIg2-NMR. The N-terminal helix of NGF which is partially blocked (Site 1)
by amitriptyline binding is shown in blue. Both H291 and H343 show CSPs. (E) Amitriptyline competes with radiolabeled NGF for binding to the full-
length TrkA receptor expressed onHEK cells with IC50∼ 60 μM. (F) Amitriptyline antagonizes downstream signaling (phosphorylation of ERK 42/44)
normally triggered by the NGF/TrkA interaction in automated immunoﬂuorescence (InCell) assays (GE Healthcare) with an EC50 ∼ 86 μM.
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residues 384−413, and strand-swapping was abolished by the
addition of a disulﬁde bond to “staple” together two intra-
molecular β-strands. The addition of ﬁve N-terminal aspartic acid
residues further improved monomer yield in the refold. Overall,
these mutations provided a stable construct, and the three-
dimensional solution NMR structure has an identical fold to that
of the TrkAIg2 domain in its native conformation bound to its
cognate ligandNGF (pdb code 1WWW). TheHSQC spectra are
robustly reproducible between batches, facilitating the rapid
determination of the weakly binding compound amitriptyline.
Because of the construct being an excised domain, we observed a
reduction in binding aﬃnity versus the full-length receptor,
however, this successfully located the binding site and generated
CSP data of suﬃcient quality to be used as additional docking
restraints by BUDE. Therefore, we suggest that in conjunction
with traditional binding and functional assays TrkAIg2-NMRwill
be a useful tool in the hit to lead optimization of therapeutics as
antagonists for pain or agonist/modulators for cholinergic
support in Alzheimer’s disease.
■ MATERIALS AND METHODS
Molecular Modeling.Modeling the Disulﬁde Staple. The residues
chosen to form a disulﬁde staple were mutated using chain X from the
crystal structure 1WWW.pdb in InsightII 2005. The complex was
soaked with a 10 Å layer of water and then energy-minimized using
Discover 2.98 (Accelrys Inc., San Diego, CA). During initial stages of
minimization, all atoms were restrained. Subsequently, all atoms were
gradually allowed freedom to move, enabling backbone and side chain
ﬂexibility as the system relaxed. Images were generated using a
combination of Chimera (University of California San Francisco), Gimp
(Gnu Image Manipulation Program, http://www.gimp.org/), and
Powerpoint (Microsoft).
Docking Amitriptyline. Guided by the amide shifts induced by the
binding of amitriptyline to the TrkAIg2-NMR construct, the compound
was maneuvered into position by hand using InsightII. The complex was
soaked with a 10 Å layer of water and then energy-minimized as
described above. To verify this position, the docking software BUDE
was used to dock amitriptyline into the center of the binding area
highlighted by the peak shifts on HSQC. Fourteen diﬀerent conformers
of amitriptyline were produced and then allowed to rotate around 360°
and translate by 12 Å in x, y, and z (a total of 8.25 million poses were
sampled). Poses were initially ranked according to their BUDE
predicted binding energy and subsequently by the minimum distance
between any amitriptyline atom and the predominant amide, HN
(proton) CSPs (T292, F303, S304, V305, H343, G344, C345, and
L346) achieved by amitriptyline binding.27
Cloning of TrkAIg2-NMR. The TrkAIg2-NMR construct was
produced in two stages. The TrkAIg2-DS1 construct represents residues
285−383 comprising the NGF binding domain of the human TrkA
receptor (P04629). A full length TrkAIg2 domain 7.2cis pET24a (+)
plasmid was used as a PCR template (residues 285−413). This template
included P285C and P367C mutations and had been engineered to
reduce mRNA secondary structure by the incorporation of silent
mutations (residues 286−290) to favor ribosome binding. These silent
mutations facilitated the eventual production of recombinant TrkAIg2-
NMR within an Escherichia coli expression system.
Stage 1. Ampliﬁcation of TrkAIg2-DS1 from TrkAIg2 d57.2cis
pET24a(+) by PCR with Pfu polymerase (Promega) using primers
(GGAATTCCATATGGATGACGATGACGATGTTA -
G C T T T T G T G C T T C A G T A C A A T T A ) a n d
(CCGCTCGAGTTATCAGAAAGGGTTGTCCATGA -
AGGCAGCCATG) produced a PCR product that was subcloned into
the NdeI and XhoI cloning sites of pET24a(+) vector (Novagen) and
transformed into a nonexpression host XL1 blue (Stratagene). Puriﬁed
mutant construct pET24a(+)TrkAIg2-DS1 was checked by sequencing
and then transformed into a BL21(DE3) E. coli (Novagen) expression
host.
Stage 2. The penta-Asp tagged TrkAIg2-NMR construct was made
by ampliﬁcation of the TrkAIg2-NMR from template pET24a(+)-
TrkAIg2-DS1 by PCR with Pfu polymerase (Promega) using the
following primers: Forward primer including an NdeI site
( G G A A T T C C A T A T G G A T G A C G A T G A C G A T G T -
TAGCTTTTGTGCTTCAGTACAATTA) and the reverse primer
incorporating an XhoI site (CCGCTCGAGTTATCAGAAAG-
GGTTGTCCATGAAGGCAGCCATG).
The ampliﬁed sequence corresponds to the DNA sequence:
ATGGATGACGATGACGATGTTAGCTTTTGTG -
CTTCAGTACAATTACACACGGCGGTGGAGATG -
CACCACTGGTGCATCCCCTTCTCTGTGGATGG -
GCAGCCGGCACCGTCTCTGCGCTGGCTCTTCA -
A TGGCTCCGTGCTCAATGAGACCAGCTTCATC -
TTCACTGAGTTCCTGGAGCCGGCAGCCAATGAGAC-
CGTGCGGCACGGGTGTCTGCGCCTCAACCAGCCCA-
CCCACGTCAACAACGGCAACTACACGCTGCTGGC-
TGCCAACCCCTGCGGCCAGGCCTCCGCCTCCA -
TCATGGCTGCCTTCATGGACAACCCTTTCTGATAA.
This corresponds to the protein sequence:
MDDDDDV S FCA S VQLHTAV EMHHWC I P F S VD -
GQPAPSLRWLFNGSVLNETSFIFTEFLEPAANETVRHGCLR-
LNQPTHVNNGNYTLLAANPCGQASASIMAAFMDNPF.
Expression of 15N or 13C/15N-Labeled TrkAIg2-NMR. To
produce 15N or 13C, 15N-labeled TrkAIg2-NMR, BL21(DE3)TrkAIg2-
NMR, cells were grown overnight in 50 mL of M9 minimal media (42
mM Na2HPO4, 22 mM KH2PO4, 9 mM NaCl, 45 mM CaCl2, 2 mM
MgSO4, 2 mg/mL thiamine (Sigma)), containing 0.2% D-glucose
13C
(for 13C preparations only), (C6) (Cambridge Isotope Laboratories), 10
mM 15NH4Cl, 99% (Cambridge Isotope Laboratories) and 0.5 mg/mL
of kanamycin (Sigma) at 37 °C. The cells were then diluted 1:10 in fresh
media and grown at 37 °C to an OD595 = 0.6. Isopropyl-D-
thiogalactoside (IPTG; Sigma) was then added to 1 mM, and the cells
were grown overnight. Unlabeled protein was produced using the same
protocol as outlined here except that minimal media with nutrient
additives were replaced by Luria−Bertani (LB) culture media
throughout.
Cells (8 g wet weight) were harvested by centrifugation at 8000 rcf at
4 °C for 15 min and resuspended into 50 mL of ice-cold, sterile 10% (v/
v) glycerol. Pellets were stored as 25 mL aliquots and frozen at −80 °C
until required. Aliquots were processed to obtain a puriﬁed inclusion
body pellet. Brieﬂy, each bacterial pellet was disrupted using a French-
Press and resuspended in 200 mL of ice-cold resuspension buﬀer (20
mM Tris pH 8.5, 10 mM EDTA) containing 100 mM NaCl and
centrifuged at 9000 rcf at 4 °C for 60 min. Three further rounds of
resuspension were then carried out with centrifugation at 9000 rcf at 4
°C for 30 min. Each pellet was resuspended in 100 mL of resuspension
buﬀer with sequential additions of 1 M NaCl, 1% (v/v) Triton X-100,
and 100 mMNaCl. Inclusion body pellets were stored overnight at−80
°C.
Refolding of 13C/15N-Labeled TrkAIg2-NMR. Each inclusion
body pellet was resuspended in 50 mL of a solubilization buﬀer
comprised of 8M urea, 40 mMTris pH 8.2, 100mMNaCl, and 1mM β-
mercaptoethanol (BME) and rocked on a platform for 3 h at room
temperature. Solubilized TrkAIg2-NMRwas collected as supernatant by
centrifugation at 9000 rcf for 1 h at 10 °C. Protein concentrations of
soluble TrkAIg2-NMR were estimated by UV absorption of aromatic
residues at 280 nm (molar extinction coeﬃcient is 12740M−1 cm−1) and
adjusted by dilution in solubilization buﬀer to 0.1 mg/mL (∼8 μM).
Diluted, soluble TrkAIg2-NMR was dialyzed 1:20 overnight against a
dialysis buﬀer comprised of 20 mM Tris at pH 8.2, containing 50 mM
NaCl, at 4 °C using 28 mm diameter dialysis tubing with a molecular
weight cutoﬀ (MWCO) of 3500 Da (Medicell International). The
partially refolded TrkAIg2-NMR was again dialyzed 1:20 overnight
against the dialysis buﬀer containing an additional 10 mM NaCl.
Refolded TrkAIg2-NMR was centrifuged at 8000 rcf at 4 °C for 60 min
to remove the majority of insoluble protein; the supernatant was
collected and stored on ice.
Puriﬁcation of 13C/15N-Labeled TrkAIg2-NMR. TrkAIg2-NMR
supernatant was loaded onto a pre-equilibrated 5 mL HiTrap Q FF
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column (Amersham Bioscience) at 5 mL/min on an AKTA fast protein
liquid chromatogaph (FPLC) (Amersham Bioscience) protein
puriﬁcation system. The column was then re-equilibrated with 5 column
volumes of buﬀer A (20mMTris pH 8.2, 10 mMNaCl). TrkAIg2-NMR
was eluted over a linear gradient consisting of 20 column volumes
starting with buﬀer A and ending with buﬀer B (20mMTris, pH 8.2, 1M
NaCl). The eluent was monitored at 280 nm. TrkAIg2-NMR eluted
with a retention time 7.7 min; fractions were pooled and stored on ice.
Prior to data acquisition, the pooled fractions of TrkAIg2-NMR were
concentrated to 6.8 mg/mL within 16 mm diameter, 3500 Da MWCO
dialysis tubing (Medicell International) using polyethylene glycol
(PEG) 20 kDa (Sigma). The dialysis bag was then transferred to
2000× volumeNMRbuﬀer (100mM sodium phosphate pH 6.9, 10mM
NaCl) and dialyzed overnight at 4 °C to exchange buﬀers and remove
any low molecular weight contaminants in the PEG.
NMR and Structure Calculation. Initial 1H−15N HSQC experi-
ments were acquired in NMR buﬀer, 20 °C (to compare TrkAIg2-NMR
and TrkAIg2-WT at 100 μM concentration) on a Varian INOVA 600
MHz spectrometer equipped with a room temperature probe. Triple
resonance experiment data were acquired at 20 °C with a cryoprobe
equipped Varian VNMRS operating at 600 MHz to assign the backbone
and side chain atoms. 15N, 13C NOESY-HSQC (nuclear Overhauser
eﬀect (enhancement) spectroscopy−heteronuclear single quantum
correlation) experiments were acquired at 600 MHz for distance
restraints. NMR data processing and analysis was performed with
NMRPipe28 and CcpNmr Analysis version 2.3.1.29 TALOS-N and
DANGLE were used to predict the backbone dihedral angles.30,31
Structures were calculated iteratively with CNS 1.2 using ARIA2.3
protocol before being water reﬁned using the RECOORD proto-
col.32−34 Restraints for the introduced disulﬁde bond were added once
the juxtaposition of the cysteine residues was observed in structure
calculations. Final structures were checked with iCing (version r1156)
(https://nmr.cmbi.ru.nl/icing/iCing.html) and PSVS (version 1.5)
(http://psvs-1_5-dev.nesg.org/).35 Figures and analyses were produced
using PyMOL (The PyMOL Molecular Graphics System, version
1.5.0.4, Schrödinger, LLC). and the UCSF Chimera package (Chimera
was developed by the Resource for Biocomputing, Visualization, and
Informatics at the University of California, San Francisco (supported by
NIGMS P41-GM103311)).36 PROFIT v2.5.2 was used to calculate the
RMSD between the closest to average NMR structure and chain X of
1WWW.pdb (Martin, A. C. R., http://www.bioinf.org.uk/software/
proﬁt/).
NMR Titrations. TrkAIg2-NMR was typically 100 μM in 100 mM
sodium phosphate, 10 mMNaCl, pH 6.9. Data was collected on a Varian
VNMRS 600 MHz NMR spectrometer equipped with a cryogenically
cooled triple resonance probe head. For the amitriptyline (Sigma, purity
>98% by TLC) titration, amitriptyline was added to the following ﬁnal
concentrations: 0, 0.015, 0.03, 0.06, 0.18, 0.3, 0.5, 1.5, 3, and 4 mM. For
comparative NMR of the NGF/TrkAIg2 complex, a stoichiometric
equivalent of NGF (preadjusted to pH 6.9) was added to the TrkAIg2-
NMR and spectra collected. CSPs (ΔδNH) were calculated according
to eq 1 given below by Pellecchia et al.24
δ δ δΔ = Δ + Δ{ }12 [( ) 0.2( ) ]NH H 2 H 2
1/2
(1)
Analytical Ultracentrifugation (AUC). AUC sedimentation
velocity experiments were conducted at 20 °C in a Beckman Optima
XL-A analytical ultracentrifuge using an An-60 Ti rotor and
sedimentation velocity cells equipped with a two-channel aluminum
centerpiece and sapphire windows. Then 410 μL solutions at 80 μM
protein concentration were loaded in the sample channel, and the
reference channel was loaded with 420 μL of buﬀer. Samples were
centrifuged at 55000 rcf (An-60 Ti rotor), with absorbance scans taken
across a radial range of 5.8−7.3 cm at 3 min intervals to a total of 180
scans. Data were ﬁtted to a continuous c(s) distribution model using
SEDFIT at a 95% conﬁdence level.37 The baseline, meniscus, frictional
coeﬃcient ( f/f 0), and systematic time-invariant and radial-invariant
noise were ﬁtted. The rmsd for the reported ﬁt was 0.007 OD. The
partial speciﬁc volume (v)̅ for the protein and the buﬀer densities and
viscosities were calculated using SEDNTERP (http://sednterp.unh.
edu/).
Native Gel Electrophoresis. The TrkAIg2-NMR construct has a
theoretical pI of 4.52, therefore 12% polyacrylamide gel electrophoresis
was carried under normal (basic) conditions with no added SDS and no
BME in the loading buﬀer.
Gel Filtration.TrkAIg2-NMR andmouse NGFwere applied to a gel
ﬁltration SuperdexTM 75 (10/300 GLS in XK16 column with 60 cm
bed height) separately and as a 1:1 ratio complex (1 mg/mL of each). A
calibration column was run in 50 mM phosphate buﬀer containing 150
μMNaCl at pH 7.4. A calibration curve with standard globular proteins
ran according to protein molecular weight: Dextran blue (2000 kDa)
(which runs at void volume), bovine serum albumin (BSA; 67 kDa),
carbonic anhydrase (29 kDa), and cytochrome C (12.4 kDa);
correlation of molecular weight with running volume (r2 = 0.98)
Cell Line Maintenance. Cells expressing the full-length human
TrkA receptors were grown as monolayers in DMEM containing 10%
fetal calf serum (FCS) (v/v), 2 mM glutamine, 10 U/mL penicillin, 0.1
mg/mL streptomycin, and 0.5 mg/mLG418 in T75 tissue culture ﬂasks.
Parent HEK cells (lacking expressed Trk receptors) were grown in
DMEM containing 10% FCS (v/v), 2mMglutamine, and antibiotics but
not G418. For assays, cells were detached from monolayers (90−95%
conﬂuent) using versene (phosphate buﬀered saline (PBS) with 1 mM
EDTA pH 8) for 5 min at 37 °C and pelleted by centrifugation (165g for
5 min at room temperature).
Radioligand Competition Assays with Amitriptyline.Displace-
ment of 125I-labeled neurotrophin NGF by amitriptyline was assessed in
HEK N3S cells expressing native human TrkA. The cell pellet was
washed three times by repeated resuspension and centrifugation, using
10 mL of assay buﬀer (PBS pH 7.4) containing 0.5 mM MgCl2 and 0.9
mM CaCl2, 0.5 mg/mL bovine serum albumin, and 1 mg/mL glucose
each time to remove any growth factors which may interfere with
subsequent assays. Cells were passed through a 21-gauge needle to
disrupt cell clumps. Following the ﬁnal wash, the supernatant was
removed; cells resuspended in 10mL of assay buﬀer and counted using a
hemocytometer. Cells were diluted to give a ﬁnal cell number in the
assay of 1 × 105 cells per tube. A positive control consisted of 100 nM
unlabeled neurotrophin, negative control was assay buﬀer, added to the
cells before 2 nM 125I-labeled neurotrophin was pipetted into each tube.
The cells were placed on a shaking platform for 30 min. Three 100 μL
aliquots from each tube were spun through 5% sucrose in assay buﬀer to
pellet the cells (20000g at 4 °C), frozen in solid CO2−ethanol bath, and
snipped (using adapted clippers to maintain reproducible depth of tip).
125I-NGF in the cell pellet was counted with a gamma counter (LKB
Wallac 1272). The assay was deemed to have been successful if the
unlabeled NGF in the positive control was able to displace >90% of the
counts compared with the negative control.
Automated Immunoﬂuorescence (InCell) Assays (GE Health-
care) with Amitriptyline. HEK293 cells were resuspended in
complete DMEM containing 10% FCS, 2 mM glutamine, 10 U/mL
penicillin, 0.1 mg/mL streptomycin, and 0.5 mg/mL G418 as necessary.
Cells were plated out at 1× 104 in 100 μL per well into polylysine coated
black-walled/clear bottomed 96-well plates (Corning CC692) and
incubated at 37 °C overnight in 5% CO2. Once cells had reached 70−
80% conﬂuence the serum concentration was reduced to 0.1% FCS
overnight.
Half the plate was populated with parent cells and the other half with
cells expressing full length glycosylated human TrkA. Parent and TrkA
cells were exposed to the same controls and compounds to ensure the
results expressed were receptor-speciﬁc and not due to, e.g., toxicity.
Each plate had dose−responses in triplicate in the presence and absence
of neurotrophin to detect antagonist and agonist activity under the same
conditions. This was to ensure any responses were TrkA receptor-
mediated.
Amitriptyline was added to the cells in PBS in 50 μL, with or without
0.5 nM NGF, respectively, for assessing antagonist or agonist activity
and incubated for 5 min at 37 °C. Cells were washed once in ice-cold
PBS (200 μL) and then placed on ice. Cells were ﬁxed using 50 μL per
well of 4% (w/v) paraformaldehyde in PBS and incubated for 30 min at
room temperature. Cells were washed once with PBS (100 μL) and
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permeabilized by adding 50 μL per well −20 °C methanol for 5 min
followed by a further wash in PBS (100 μL). Nonspeciﬁc binding was
reduced by incubating with 50 μL per well 10% goat serum in PBS at
room temperature (2 h) and washed once with PBS (100 μL) before 30
μL per well at 1:500 dilution anti-phosphoERK (pERK) antibody (New
England Biolabs Ltd.) was added to the wells. Plates were covered and
incubated in a moist chamber overnight at 4 °C. The cells were washed
three times in PBS prior to application of 30 μL per well of the secondary
antibody goat anti-rabbit Alexa 546 (Invitrogen) at 1/300 in PBS plus
1% goat serum and 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-
Aldrich) 1 mg/mL diluted to 1/10000 for nuclear staining. Plates were
incubated for 90 min in the dark at room temperature and then washed
three times with 200 μL of PBS per well and stored in 200 μL of PBS at 4
°C until read in the InCell 1000 analyzer (GE Healthcare).
Data were collected using excitation λ 535 nm and emission λ 620 nm
for 2000 ms exposure for AlexaFluor secondary antibody signal for ERK
activation (pERK 1/2). DAPI (as nuclear stain) was assessed using λ
excitation 360 nm and emission λ 460 nm with 600 ms exposure. Data
were analyzed and presented as pERK intensity per cell.
NGF-Dependent Cell Proliferation in PC12 Cells. For eﬀects of
TrkAIg2-NMR on NGF-dependent PC12 cell proliferation or survival,
CellTiter 96 aqueous nonradioactive cell proliferation reagents 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt (MTS) and the electron coupling reagent
phenazinemethosulfate (PMS) (Sigma) were added to cells as per
manufacturer’s instructions. Cells were seeded at a cell density of 10000
cells per well into 96-well plates containing 100 μL of complete cell
culture media (DMEM, 1% (v:v) penicillin/streptomycin glutamine).
Mouse NGF was added to give a ﬁnal concentration of 5 ng/mL. Serial
dilutions of TrkAIg2 or TrkAIg2-NMR were added to the wells. MTS
and PMS solutions were then added with ﬁnal concentrations of 333 μg/
mL MTS and 25 μM PMS. The assay was performed in triplicate at
incubation times of 1, 2, and 3 h at 37 °C with 5% CO2 to allow color
development. Absorbance at 490 nm was recorded on a BIOHIT BP-
800 spectrophotometer (Helsinki, Finland).
Neurite Outgrowth Assay. 15N labeled TrkAIg2-NMR construct
was diluted to achieve a ﬁnal concentration in the assay of 4.5 μM, 2.25
μM, 1.125 μM, 562 nM, 281 nM, and 140 nM. NGF (human
recombinant, Sigma) evokes neurite outgrowth on PC12 cells at a
concentration of 0.04 nM after 3 days incubation at 37 °C. Buﬀer
controls with and without NGF were used to verify that any suppression
of neurite outgrowth was due to the protein and not the buﬀer in which
it was dissolved. A positive control consisted of TrkAIg2-WT. Other
control wells consisting of PC12 cells with and without NGF (in media)
were included to check for cell responsiveness. The cells were removed
from 90% conﬂuent T75 ﬂask in versene and resuspended in complete
media (Dulbecco’s Modiﬁed Eagle Medium (DMEM) (Gibco BRL)
supplemented with 10% (v/v) fetal bovine serum (FBS, Sigma), 1% (v/
v) penicillin/streptomycin solution (Sigma), and 2 mM L-glutamine
(Gibco BRL). The cell number was adjusted to 4 × 104 per mL and 0.5
mL cells were seeded into collagen coated 24-well plates, 0.5 mL per
well. TrkAIg2-NMR construct protein was diluted to 2× ﬁnal
concentration in full media. Neurite outgrowth was assessed semi-
quantitatively on a scale of 0−4 as described previously38 The assay was
valued in quadruplicate with wells blinded by two independent
assessors.
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lular-signal-regulated kinase; MWCO, molecular weight cutoﬀ;
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